Brokerages expect OvaScience Inc (NASDAQ:OVAS) to post earnings per share of ($0.29) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for OvaScience’s earnings, with estimates ranging from ($0.32) to ($0.28). OvaScience reported earnings of ($0.64) per share during the same quarter last year, which indicates a positive year over year growth rate of 54.7%. The company is scheduled to issue its next earnings results on Thursday, March 1st.

On average, analysts expect that OvaScience will report full year earnings of ($1.48) per share for the current financial year, with EPS estimates ranging from ($1.51) to ($1.47). For the next year, analysts forecast that the business will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.33) to ($0.92). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for OvaScience.

OVAS has been the subject of several recent analyst reports. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Wednesday, January 10th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of OvaScience in a report on Monday, November 6th.

Several large investors have recently modified their holdings of OVAS. GMT Capital Corp purchased a new stake in shares of OvaScience during the 3rd quarter worth about $1,138,000. Broadfin Capital LLC purchased a new stake in shares of OvaScience during the 2nd quarter worth about $429,000. Sabby Management LLC grew its holdings in shares of OvaScience by 20.2% during the 2nd quarter. Sabby Management LLC now owns 509,300 shares of the biotechnology company’s stock worth $795,000 after purchasing an additional 85,525 shares during the period. Susquehanna International Group LLP grew its holdings in shares of OvaScience by 87.2% during the 2nd quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 52,538 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in shares of OvaScience by 28.8% during the 2nd quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock worth $256,000 after purchasing an additional 36,720 shares during the period. Institutional investors and hedge funds own 54.80% of the company’s stock.

OvaScience (OVAS) traded up $0.04 on Friday, reaching $0.97. The company’s stock had a trading volume of 1,479,934 shares, compared to its average volume of 871,694. The stock has a market cap of $33.34, a PE ratio of -0.53 and a beta of 3.37. OvaScience has a 52 week low of $0.90 and a 52 week high of $2.05.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/09/brokerages-expect-ovascience-inc-ovas-to-announce-0-29-earnings-per-share.html.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get a free copy of the Zacks research report on OvaScience (OVAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.